FIGURE 3 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Year: 2024
Type: other
Abstract: Genes differentially expressed on treatment day 8 versus treatment baseline, as a function of TPST-1120 exposure. A, Linear associations of day 8 log2 fold change in expression levels of indicated genes and TPST-1120 AUC0–24. All genes exhibited FDR P < 0.05 and effect size > 0.5. Data are shown for both TPST-1120 monotherapy (part 1) and TPST-1120 + nivolumab combination therapy (part 2). An AUC0–24 value of 66,180 ng⋅hour/mL was excluded as an outlier. B, Comparison of differential gene expression on day 8 as a function of AUC0–24 tertile. Median elevation magnitudes in highest tertile were statistically increased above baseline values (*, P < 0.05 by Wilcoxon pair-wise comparison).
Authors: Mark Yarchoan, John D. Powderly, Bruno R. Bastos, Thomas B. Karasic, Oxana V. Crysler, Pamela N. Munster, Meredith A. McKean, Leisha A. Emens, Yvonne M. Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C. Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W. Dubensky, Sam H. Whiting, Susanna V. Ulahannan
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4394914901